PAB

0.00%

0.6¢ patrys limited

Thank you Iceberg and apologies to Orion

First 693 Last

Share
Profile

Follow
redant

3,155 Posts.

249

22/08/18

21:50

Post #: 35108597
Share

Originally posted by Iceberg ↑

To set the record straight: Orion is quite right on his recollection (albeit a single patient treated with PAT-SM6 in combination therapy). Particular mention is made of multiple myeloma lesions found in the testes which improved when this patient was dosed with PAT-SM6 dosed in combination!!

Melbourne, Australia; 28 May, 2014: Patrys Limited (ASX: PAB; “the Company”, a clinical stage biotechnology company, is pleased to announce the clinical results from a patient treated with PAT-SM6 in combination with other marketed multiple myeloma drugs.
The patient is a 61 yr old man with IgG kappa multiple myeloma diagnosed in 2013. Initially he was treated with four cycles of combination chemotherapy (Pomalyst, Adriamycin, Dexamethasone and high-dose Melphalan) followed by an autologous stem cell transplant (SCT). The patient initially responded well and went into complete remission (CR). Six months post SCT, the patient’s disease relapsed and he received another four cycles of combination chemotherapy including Revlimid. At the end of the four cycles, the patient suffered another relaspe of his disease with several extramedullary (outside of the bone marrow) tumours appearing. These tumours involved multiple soft tissues and the testes. There was also evidence of tumour within the bone-marrow (intramedullary).
Preclinical data have shown that Patrys’ PAT-SM6, when used in combination with several marketed myeloma drugs, induces specific binding and killing of multiple myeloma cells that are otherwise resistant to drug therapy. More specifically, PAT-SM6 has been shown to be highly synergistic with proteosome inhibitors (for example Velcade).
On the basis of these preclinical data, Professor Einsele (University of Würzburg Hospital) decided to treat the relapsed patient with a combination of Velcade, Revlimid and PAT-SM6. After three doses of this combination therapy, a PET-CT scan revealed significant shrinkage of both the extramedullary and the intramedullary lesions. Of particular note was the disappearance of the tumour in the testes. The patient has since gone on to receive additional treatment for his remaining disease.
Patrys CEO, Dr Marie Roskrow, commented “This patient, who has very difficult to treat myeloma, had an excellent response to PAT-SM6 when it was used with other myeloma drugs. The fact that he received a proteosome inhibitor (Velcade) as part of the treatment protocol with PAT-SM6 is particularly important as Patrys’ next clinical trial will be using a second generation proteosome inhibitor (Kyprolis (Carfilzomib)) in combination with PAT-SM6.

Expand

Thank you Iceberg and apologies to Orion

PAB Price at posting: 3.7¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NAM

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

The market's shrugged at China's stimulus measures all year. Why is this one different?

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

There are more pages in this discussion • 1,179 more messages in this thread...

First 693 Last

Add PAB (ASX) to my watchlist

(20min delay)
Last 0.6¢		Change 0.000(0.00%)		Mkt cap ! $12.34M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
3	1283356	0.6¢

Sellers (Offers)

Price($)	Vol.	No.
0.7¢	4958674	5

View Market Depth

No.	Vol.	Price($)
3	1283356	0.006
12	4399891	0.005
8	5414000	0.004
5	5899016	0.003
1	2520000	0.002

Price($)	Vol.	No.
0.007	4958674	5
0.008	1521890	4
0.009	1040280	4
0.010	355230	3
0.012	1292407	3

Last trade - 16.12pm 27/09/2024 (20 minute delay)

PAB (ASX) Chart

Day chart unavailable

Thank you Iceberg and apologies to Orion

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Zeta Resources seeks to resolve the Panoramic takeover story

The market's shrugged at China's stimulus measures all year. Why is this one different?

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thank you Iceberg and apologies to Orion

Top Stories

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Zeta Resources seeks to resolve the Panoramic takeover story

The market's shrugged at China's stimulus measures all year. Why is this one different?

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News